BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26520037)

  • 1. Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?
    Horcajada-Reales C; Pulido-Pérez A; Suárez-Fernández R
    Actas Dermosifiliogr; 2016; 107(1):23-33. PubMed ID: 26520037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
    Owen CE; Jones JM
    Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Harr T; French LE
    Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
    Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
    J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
    Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
    J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe cutaneous adverse reactions to drugs.
    Duong TA; Valeyrie-Allanore L; Wolkenstein P; Chosidow O
    Lancet; 2017 Oct; 390(10106):1996-2011. PubMed ID: 28476287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The major SCAR syndromes].
    Piérard GE; Lesuisse M; Piérard-Franchimont C
    Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments for Severe Cutaneous Adverse Reactions.
    Cho YT; Chu CY
    J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Generalized Exanthematous Pustulosis Simulating Toxic Epidermal Necrolysis: Overlapping Processes.
    García Abellán J; Matarredona Catalá J; Jaen Larrieu A; Valencia Ramírez I
    Actas Dermosifiliogr (Engl Ed); 2018 Jun; 109(5):460-462. PubMed ID: 29402393
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe adverse drug reactions.
    Teo YX; Walsh SA
    Clin Med (Lond); 2016 Feb; 16(1):79-83. PubMed ID: 26833523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe acute generalized exanthematous pustulosis with blistering mimicking toxic epidermal necrolysis, associated with a primary mumps infection.
    Azib S; Florin V; Fourrier F; Delaporte E; Staumont-Sallé D
    Clin Exp Dermatol; 2014 Aug; 39(6):723-5. PubMed ID: 24986490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Reactions in Major Types of Oncological Treatment.
    Kozubek P; Wołoszczak J; Gomułka K
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions.
    Guvenir H; Arikoglu T; Vezir E; Misirlioglu ED
    Curr Pharm Des; 2019; 25(36):3840-3854. PubMed ID: 31696807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature.
    Peermohamed S; Haber RM
    Arch Dermatol; 2011 Jun; 147(6):697-701. PubMed ID: 21690532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of cutaneous adverse drug reactions].
    Ingen-Housz-Oro S
    Rev Prat; 2023 Mar; 73(3):307-313. PubMed ID: 37289124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis in patients with psoriasis.
    Smith VM; Pollock B; Wilkinson SM; Rose RF
    Clin Exp Dermatol; 2016 Jul; 41(5):561-2. PubMed ID: 26931079
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
    Hadavand MA; Kaffenberger B; Cartron AM; Trinidad JCL
    J Am Acad Dermatol; 2022 Sep; 87(3):632-639. PubMed ID: 32926975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse cutaneous drug eruptions: current understanding.
    Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
    Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Hypersensitivity Reactions.
    Wilkerson RG
    Immunol Allergy Clin North Am; 2023 Aug; 43(3):473-489. PubMed ID: 37394254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions.
    Gelincik A; Cavkaytar O; Kuyucu S
    Curr Pharm Des; 2019; 25(36):3881-3901. PubMed ID: 31692425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.